Your browser doesn't support javascript.
loading
Risk for Anaphylactic Reaction from Cardiac Catheterization in Patients Receiving ß-Adrenergic Blockers or Angiotensin-Converting Enzyme-Inhibitors.
Smith, Martin A; Newton, Lisanne P; Barcena Blanch, Maria A; Cuervo-Pardo, Lyda; Cho, Leslie; Newton, David; Wang, Xiaofeng; Li, Manshi; Lang, David M.
Afiliação
  • Smith MA; Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: smithm49@ccf.org.
  • Newton LP; Coastal Allergy and Asthma, Savannah, Ga.
  • Barcena Blanch MA; Asthma and Allergy Associates of Florida, Miami, Fla.
  • Cuervo-Pardo L; University of Florida, Gainesville, Fla.
  • Cho L; Cleveland Clinic Foundation, Cleveland, Ohio.
  • Newton D; Memorial Health, Savannah, Ga.
  • Wang X; Cleveland Clinic Foundation, Cleveland, Ohio.
  • Li M; Cleveland Clinic Foundation, Cleveland, Ohio.
  • Lang DM; Cleveland Clinic Foundation, Cleveland, Ohio.
J Allergy Clin Immunol Pract ; 8(6): 1900-1905, 2020 06.
Article em En | MEDLINE | ID: mdl-31683029
BACKGROUND: ß-Adrenergic blockers (BBs) have been associated with increased risk for severe anaphylactic reaction (AR) from contrast media; however, this was shown with intravenous contrast media, before widespread use of low osmolar contrast media, angiotensin-converting enzyme-inhibitors (ACE-Is), and cardioselective BBs. OBJECTIVE: To assess the risk for AR during cardiac catheterization (CC) associated with BB or ACE-I exposure. METHODS: Patients who experienced adverse reactions during CC from January 2004 to December 2013 were identified; 1 to 2 matched controls were assigned for each case. We analyzed AR rates in association with demographic variables, medication exposures (BBs, ACE-Is, angiotensin-receptor blockers, aspirin), and comorbidities: cardiovascular disorders, asthma, and atopy. RESULTS: We analyzed 71,782 CCs. Of these, severe 70 reactors were identified-46 (0.06%) fulfilled AR criteria. There were 35 cases of mild to moderate AR and 11 cases of severe AR (0.015%). There were no significant differences in age (61.3% vs 61.5%), sex (63% vs 64% males), cardiovascular disorder rate (78% vs 93%), and exposure to BBs (46% vs 51%; cardioselective: 77% vs 80%) and ACE-Is (37.0% vs 37.2%) in cases versus controls. Via multivariate logistic regression, BB exposure was not associated with greater AR frequency (P = .35) or severity (P = .40). Neither cardioselective BBs (P = 0.2) nor noncardioselective BBs (P = .5) influenced AR severity. ACE-Is had no effect on AR frequency (P = .35) or severity (P = .14). Lower AR frequency was associated with cardiovascular disorder (P = .01). CONCLUSIONS: In this case-control study, severe AR was rarely observed. Exposure to BBs or ACE-Is did not significantly influence AR frequency or severity; however, most BBs were cardioselective. Our findings imply that cardioselective BB or ACE-I suspension is not warranted in association with CC.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Anafilaxia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Anafilaxia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2020 Tipo de documento: Article